Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."
Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down
Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses
Earnings of Sensex companies to decline up to 8% this year on economic concerns; fiscal stimulus may help recovery: Analyst
At present, Indian indices are under-performing as compared to others and a package from the government can help cover the ground, he said.
On 1 May, Glenmark Pharmaceuticals said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.
Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag
Sensex tumbled 260 points on Friday, dragged by losses in banking and financial stocks as RBI's rate cut and other measures to prop up the economy failed to meet market expectations.
Markets close day's session on buoyant note: Sensex up 622 points, Nifty above 9,050-mark; HDFC top gainer, surges over 5%
The Sensex settled 622.44 points or 2.06 percent higher at 30,818.61, while the NSE Nifty rose 187.45 points, or 2.11 percent, to end at 9,066.55
Market ends on positive note; Sensex jumps 637 points, Nifty above 9,350; Re settles higher at Rs 75.46 against dollar
The Nifty bank index was up by 4 percent. Besides, sharp buying was also witnessed in the auto and metal stocks.
Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19
Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19
Markets close on positive note: Sensex 199 points up, propelled by strong gains in RIL; rupee closes higher
Reliance Industries was the biggest contributor to the gains on the index, jumping over 3 percent after the company announced that US-based PE firm Vista Equity Partners will buy 2.32 percent stake in Jio Platforms for Rs 11,367 crore.
Sensex ends over 260 points lower at 31,454; Nifty falls 87.90 points to 9,206; except energy, infra, all sectoral indices in red
The Sensex surrendered all its early gains to end 262 points lower on Tuesday due to emergence of a sudden sell-off in financial stocks at the fag-end of the sessio
Drug maker Lupin on Thursday said the US health regulator has closed the inspection of its manufacturing facility in Pithampur, Madhya Pradesh
Coronavirus outbreak highlighted vulnerabilities in medical manufacturing supply chain: Fitch Solutions
With pharmaceutical supply chains under immense pressure due to COVID-19, China's role as a global ingredient producer has come under scrutiny, Fitch Solutions has said
Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., said on Thursday it has received the Establishment Inspection Report (EIR) from the USFDA (the United States Food and Drug Administration) for the pre-approval inspection at two of its biologics manufacturing facilities in Bengaluru
Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh
Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur
Coronavirus Outbreak: Which sectors will bounce back, which will take time post-lockdown, experts weigh in
Sectors that depend on people's behaviour would take the longest time to recover after the end of the lockdown period, while those curbed by the government to contain the spread of coronavirus are set for a bounce-back immediately after the restrictions are removed, say experts
Coronavirus outbreak cripples all major sectors in country; sharp fall in revenues, unemployment to rise in coming days
The coronavirus outbreak happened to be a major setback for hopes of a revival in beleaguered auto sector of the country, which had grappled in the red zone due to sharp fall in demand for over two quarters.
NSE Indices' Index Maintenance Sub-Committee has decided to make the replacement of stocks in various indices as part of its periodic review. These changes would become effective from March 27, 2020.
UBS cuts India GDP growth forecast to 5.1% for FY21 on fears around coronavirus outbreak, weak domestic credit growth
The GDP growth is set to slip to a decadal low of 5 percent for FY20 as per official estimates and hopes of a revival are being pinned on the next fiscal